Filtered By:
Source: Oncology Letters
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 221 results found since Jan 2013.
Integrin α5 promotes migration and invasion through the FAK/STAT3/AKT signaling pathway in icotinib-resistant non-small cell lung cancer cells
Oncol Lett. 2021 Jul;22(1):556. doi: 10.3892/ol.2021.12817. Epub 2021 May 24.ABSTRACTPatients with non-small cell lung cancer (NSCLC) treated with EGFR-tyrosine kinase inhibitors (TKIs) ultimately develop drug resistance and metastasis. Therefore, there is a need to identify the underlying mechanisms of resistance to EGFR-TKIs. In the present study, colony formation and MTT assays were performed to investigate cell viability following treatment with icotinib. Gene Expression Omnibus datasets were used to identify genes associated with resistance. Wound healing and Transwell assays were used to detect cell migration and inv...
Source: Oncology Letters - June 4, 2021 Category: Cancer & Oncology Authors: Yang Yang Yizhe Wang Xiaofang Che Kezuo Hou Jie Wu Chunlei Zheng Yang Cheng Yunpeng Liu Xuejun Hu Jingdong Zhang Source Type: research
Inhibition of aquaporins as a potential adjunct to breast cancer cryotherapy
Oncol Lett. 2021 Jun;21(6):458. doi: 10.3892/ol.2021.12719. Epub 2021 Apr 8.ABSTRACTCryoablation is an emerging type of treatment for cancer. The sensitization of tumors using cryosensitizing agents prior to treatment enhances ablation efficiency and may improve clinical outcomes. Water efflux, which is regulated by aquaporin channels, contributes to cancer cell damage achieved through cryoablation. An increase in aquaporin (AQP) 3 is cryoprotective, whereas its inhibition augments cryodamage. The present study aimed to investigate aquaporin (AQP1, AQP3 and AQP5) gene expression and cellular localization in response to cry...
Source: Oncology Letters - April 28, 2021 Category: Cancer & Oncology Authors: Haifa Alkhalifa Fatima Mohammed Sebastien Taurin Khaled Greish Safa Taha Salim Fredericks Source Type: research
Synergistic effects of olaparib combined with < em > ERCC1 < /em > on the sensitivity of cisplatin in non-small cell lung cancer
In conclusion, olaparib combined with ERCC1 expression may enhance the sensitivity of cisplatin in NSCLC. These findings may provide novel insight for the improvement of platinum drug sensitivity and treatment of NSCLC.PMID:33747222 | PMC:PMC7967929 | DOI:10.3892/ol.2021.12626
Source: Oncology Letters - March 22, 2021 Category: Cancer & Oncology Authors: Kejie Xie Xiaoyan Ni Shanmei Lv Guozhong Zhou Honger He Source Type: research
